Call: (979) 848-0800
DELIVERING, EXPANDING, ADVANCING The science of radiopharmaceuticals


R. Keith Frank, Ph.D.


Dr. Frank is a co-founder of IsoTherapeutics. A synthetic organic chemist by training, he has spent the first 23 years of his career at The Dow Chemical Company. His principle activity was in the development of radiopharmaceuticals, including two approved products (Quadramet® and I-125 IotrexTM). He holds 22 US patents and has over 30 publications.

Dr. Frank initiated and led ChelaMedSM radiopharmaceutical services at Dow. In that role he helped other companies develop radiopharmaceuticals and taught them about isotopes and conjugation chemistry. He also has expertise in developing tumors in animal studies and in radiation dosimetry.

Jaime (Jim) Simón, Ph.D.


Dr. Simón is a co-founder of IsoTherapeutics. He is a radiochemist by training and spent 25 years at The Dow Chemical Company where he was responsible for a group dedicated to developing new pharmaceutical technologies. He holds over 50 US patents, including the key patents covering Quadramet® (153Sm-EDTMP) for the treatment of bone cancer and STR (166Ho-DOTMP) for safely ablating bone marrow prior to bone marrow transplants. Dr Simón has over 70 publications.

Key Contacts

Lance Cooper

Business Development Director

Mr. Cooper spent 32+ years at The Dow Chemical Company where his career was divided between polyurethane chemicals Technical Service & Development and chelation technology R&D. In his technical service role he interfaced with multiple large corporate accounts and led numerous product development projects interfacing with many functions including sales, marketing, production, R&D, EH&S and product stewardship. In his R&D role he was involved in chelation technology applied to H2S abatement, cleaning products and radiopharmaceuticals. Lance graduated from the University of Colorado – Boulder with a degree in chemistry. He holds 8 U.S. patents in various technologies.

Shannon Phillips, Ph.D.

Director of Quality

Dr. Phillips is an analytical chemist by training, focusing on chromatographic development and validation. The first 5 years of her career was spent at the Pharmaceutical Research Institute in Analytical R&D at Bristol-Myers Squibb Company (BMS). During this time Dr. Phillips made significant technical contributions to the CMC filing for an NDA application including hands-on technical transfer of methodology in Europe. She was the analytical project leader for two products in early stage development, and she helped design and implement two GMP-regulated laboratories while at BMS. During her three years at The Dow Chemical Company she provided a broad range of technical expertise in Analytical Sciences in Core R&D. Dr. Phillips is a graduate of The Ohio State University and has authored five peer reviewed publications.

Kimberly Miller

Executive Assistant

Mrs. Miller is a Certified Purchasing and Supply Chain Manager, receiving her certification from UH-CLC. She was the first graduate of this program at the Business School. Mrs. Miller’s career consists of 23 years at Rhodia/Rhone Poulenc as a Corporate Buyer and Inventory Manager and 5 years at TDECU as the Director of Facilities and Purchasing. Mrs. Miller traveled extensively with Rhodia implementing new maintenance software systems and training employees at various sites. She has experience in all aspects of office management, project management and vendor management.


A small company with high caliber people. This company helped me address critical questions posed by the FDA.

Ebrahim S. Delpassand, M.D.
Chairman & Medical Director Excel Diagnostics

IsoTherapeutics has proven to be a partner able to adapt quickly to FUJIFILM's changing needs. Within two weeks, they had documentation in place for the preparation of two new blood testing kits, and prepared GMP batches of each for our clinical sites.

Takeaki Suzuki, Ph.D.
Associate Director, Drug Development, Head of Operations, FUJIFILM Pharmaceuticals USA, Inc.

The combination of R&D, cGMP and small animal testing facilities makes IsoTherapeutics the ideal partner for our radiopharmaceutical programs - from initial development to commercialization. The skills that IsoTherapeutics have brought to our product development programs over the past decade have proven to be a major contribution to our success.

Nigel R. Stevenson, Ph.D.
COO, Serene, LLC

Contact Us

IsoTherapeutics Group, LLC
1004 S. Velasco St.
Angleton, TX 77515

Phone (979) 848-0800
Fax (979) 848-0807